Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12345678910111213...2425»
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, Adverse events, Adverse drug reaction:  Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database. (Pubmed Central) -  Mar 15, 2022   
    All national publicly-available aggregated ADR reports recorded from 2002 to 2020 into the Reports of Adverse Reactions of Medicines (RAM) system and all complete Sicilian data reported into the Italian spontaneous reporting system (SRS) database having as suspected drugs interferon β-1a (IFN β-1a), interferon β-1b (IFN β-1b), peginterferon β-1a (PEG-IFN β-1a), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FNG), teriflunomide (TRF), dimethyl fumarate (DMF), alemtuzumab (Alem), ocrelizumab (OCZ), or cladribine (Cladr), were collected...The reporting of drugs-related ADRs in MS were mostly reported in the literature, but some unknown ADRs were also found. However, further studies are necessary to increase the awareness about the safety profiles of new drugs on the market.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. (Pubmed Central) -  Mar 11, 2022   
    A potential safety signal detected in the sensitivity analysis concerning Interferon-beta1a, Alemtuzumab, requires further evaluation with more robust evidence. These cases highlight that if a patient suspected to have MS does not respond to conventional treatments such as alemtuzumab, a search for alternative diagnoses such as MOG antibody disease may be warranted.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Two-Year Interim Analysis of the TREAT-MS Alemtuzumab Study in Germany Differentiated by Direct Pretreatment (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_3762;    
    Hereof, 17.0% (n=84) were treatment-naïve and 83% received the following last previous therapy prior to alemtuzumab: fingolimod (28.5%, n=141), natalizumab (21.1%, n=104), basic injectables (glatiramer acetate or interferon-beta; 20.6%, n=102), or basic orals (dimethyl fumarate or teriflunomide; 12.8%, n=63)... These interim results indicate that alemtuzumab shows good real-world effectiveness and safety across patient subgroups with different pretreatment history but less pronounced effects after fingolimod pretreatment.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Guillain-Barré Syndrome After Alemtuzumab Treatment in a Patient with Multiple Sclerosis: a Case Report (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_3123;    
    Clinical monitoring and mechanistic studies continue to address this question. There are several reports of GBS after alemtuzumab treatment in patients with leukemia.However,in MS patients,there is only one published case of acute motor axonal neuropathy that occurred after the alemtuzumab treatment.GBS should also be considered in patients with subacute neurological worsening after the alemtuzumab treatment.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Covid19 in Multiple Sclerosis Patients in Dubai : Observational Study (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2876;    
    A higher EDSS score, progressive disease, use of rituximab, and ocrelizumab(antiCD20 therapy) were associated with the mortality encountered. Age, sex, smoking history, and duration of MS were not independent risk factors for increased severity or adverse COVID-19 disease outcomes.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    IgG4-Related Disease as an Autoimmune Consequence of Alemtuzumab Therapy for Management of Multiple Sclerosis ([VIRTUAL]) -  Mar 6, 2022 - Abstract #AAN2022AAN_1853;    
    Management options include steroids and rituximab, further supporting the role of B cells in its pathophysiology. We describe a presentation of IgG4-related disease, not previously described to be associated with, but likely to be, the result of secondary autoimmunity following treatment with Alemtuzumab for multiple sclerosis.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal, Adverse events:  Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. (Pubmed Central) -  Mar 4, 2022   
    P
    All consecutive reports of DMTs prescribed to pwMS (alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon-β, natalizumab, ocrelizumab, and teriflunomide), and their serious adverse event cases were eligible, excluding those reporting immunosuppressant DMTs used as anticancer therapies...A close and regular cancer screening in pwMS treated with natalizumab, interferon-β, dimethyl fumarate, and fingolimod may be warranted, even for persons at a younger age. Trial Registration NCT04237337.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Biomarker, Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Neurofilaments for NEDA Assessing in MS (clinicaltrials.gov) -  Feb 25, 2022   
    P=N/A,  N=21, Terminated, 
    No abstract available N=60 --> 21 | Trial completion date: Jul 2020 --> Jan 2022 | Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Jan 2022; Under recruitment
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Breast Cancer in Multiple Sclerosis Patients Treated with Disease Modifying Therapies (Virtual Poster Hall) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_550;    
    Further examination of odds ratios showed additional increases with INFb1a and NAT. The lowest proportions were reported with ALE and FIN; however, further examination of odds ratios showed decreases with INFb1b, GA, TER, and ALE.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
    PIRA among MS Patients Treated with Ocrelizumab and Alemtuzumab; A Real World Study. (Exhibit Hall A) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_422;    
    In the real-world setting, among RRMS patients, PIRA accounted for most of the disability accumulation, confirming the occurrence of an underlaying progressive course since the early stage of the disease. PIRA events are more likely to occur in older patients, suggesting a reduced efficacy of highly active treatments with increasing age.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Cladribine, a Novel Treatment For Refractory Intermediate Uveitis in Multiple Sclerosis. (Exhibit Hall A) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_389;    
    One reported case in the literature achieved remission of refractory MS-associated uveitis with alemtuzumab, a potent lymphopenic agent targeting both B cells and T cells (1)...She was treated with ocrelizumab for her MS with the hope of also improving her ocular inflammatory disease... To our knowledge, this is the first case report of cladribine treatment for MS-associated intermediate uveitis.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Humoral and cellular immune response after SARS CoV-2 vaccine in patients with Multiple Sclerosis treated with immunosuppressant (Virtual Poster Hall) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_291;    
    Eighty patients were evaluated in treatment with: 10 teriflunomide, 6 dimethyl fumarate, 13 cladribine, 8 fingolimod, 7 natalizumab, 27 ocrelizumab, 4 alemtuzumab, 5 rituximab... In our cohort the majority of immunosuppressed MS patients who are not capable of inducing an adequate humoral response, present a cellular immune response after administration of the SARS CoV-2 vaccine.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Review, Journal:  Non-Conventional Clinical Uses of TSH Receptor Antibodies: The Case of Chronic Autoimmune Thyroiditis. (Pubmed Central) -  Feb 19, 2022   
    At present, however, the most relevant recommendation for the use of TRAb assay is in patients with CAT secondary to a known agent; in particular, after treatment with alemtuzumab for multiple sclerosis. In conclusion, the routine use of anti-TSH receptor antibodies (either TRAb or TSAb/TBAb) assay cannot be suggested at the present for diagnosis/follow up of patients affected by CAT; there are, however, several conditions where their detection can be clinically relevant.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia. (Pubmed Central) -  Feb 19, 2022   
    New DMTs are not as readily available in Croatia as they are in some countries. However, there is a continuous increase in the number of prescriptions, along with growing costs in pharmacological treatment of multiple sclerosis, and this can be expected to become even more pronounced in the following years, due to the abundance of new therapeutic options that are steadily becoming available.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Review, Journal:  Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. (Pubmed Central) -  Feb 17, 2022   
    To date, there has been no evidence suggesting that treatment with fingolimod, dimethyl fumarate, or natalizumab leads to antibody deficiency...Immune supplementation employing Ig replacement therapy might reduce morbidity and mortality associated with SIDs in neurological conditions. In light of the broad range of existing and emerging therapies, the potential for SID warrants urgent consideration among neurologists and other healthcare professionals.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. (Pubmed Central) -  Feb 4, 2022   
    In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sclerosis, including beta interferon, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, cladribine, natalizumab, alemtuzumab, and ocrelizumab...For some DMTs, screening for hepatitis B virus and hepatitis C virus is required before starting treatment and a monitoring or antiviral prophylaxis schedule has been established. Beta interferon, glatiramer acetate, natalizumab, and alemtuzumab are relatively contraindicated in autoimmune hepatitis due to the risk of disease exacerbation.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. (Pubmed Central) -  Jan 27, 2022   
    Teriflunomide, a first-line oral drug used in the treatment of relapsing-remitting MS (RRMS), may display antiviral activity by depleting cellular nucleotides necessary for viral replication...For example, fingolimod, might be highly beneficial during the hyperinflammatory stage of COVID-19 for a number of mechanisms including the reinforcement of the endothelial barrier. Caution is suggested for the use of natalizumab, cladribine, alemtuzumab, and ocrelizumab, although MS disease recurrence after discontinuation of these drugs may overcome a potential risk for COVID-19 infection.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Clinical data, Journal:  Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. (Pubmed Central) -  Jan 27, 2022   
    Caution is suggested for the use of natalizumab, cladribine, alemtuzumab, and ocrelizumab, although MS disease recurrence after discontinuation of these drugs may overcome a potential risk for COVID-19 infection. Initiating MS-therapy with heDMT significantly reduced the risk of 5-year disability progression and relapse compared to using meDMT as first DMT choice in propensity-matched groups of Finnish MS-patients.